David Piacquad - 28 May 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Michael Milligan, as Attorney-in-Fact for David Piacquad
Issuer symbol
NMRA
Transactions as of
28 May 2025
Net transactions value
$0
Form type
4
Filing time
30 May 2025, 18:30:37 UTC
Previous filing
18 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Piacquad David Director C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for David Piacquad 30 May 2025 0001602343

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -46,455 -100% 0 28 May 2025 Common Stock 46,455 $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -28,571 -100% 0 28 May 2025 Common Stock 28,571 $1.69 Direct F2, F3
transaction NMRA Stock Option (Right to Buy) Award +46,455 46,455 28 May 2025 Common Stock 46,455 $0.7200 Direct F1, F2, F4
transaction NMRA Stock Option (Right to Buy) Award +28,571 28,571 28 May 2025 Common Stock 28,571 $0.7200 Direct F2, F3, F4
transaction NMRA Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 28 May 2025 Common Stock 80,000 $0.7200 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
F2 On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
F3 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.
F4 On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
F5 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025.